Preventing cancer recurrence with novel antibody–drug conjugates
Presidential presentations in early breast cancer provide first evidence of ADCs rapidly moving into the curative setting across multiple cancer types
Trastuzumab deruxtecan is moving to the curative setting in early HER2-positive breast cancer
Positive findings from the DESTINY-Breast05 and DESTINY-Breast11 trials suggest that a paradigm change in the treatment of high-risk patients may be imminent
Head and neck cancers: should research continue to invest in immunotherapy?
Despite growing disappointing results from clinical trials, focus should now turn to the design of studies to better reflect tumour heterogeneity
Is thymic health a novel tumour-agnostic biomarker?
Study findings reveal that good thymic health, based on an AI-derived algorithm, is associated with improved survival after immunotherapy in different tumour types
Optimising cancer care for individual patients is key to improving outcomes for all
An ESMO roadmap addresses how the new challenges in oncology can be transformed into opportunities for the benefits of oncology professionals and patients with cancer
How will computational and AI tools guide future anticancer strategies?
Growing evidence shows that AI models can predict a patient's disease trajectory and signal the need for early therapeutic intervention
Mentoring is key to address the gender gap in oncology
Receiving the 2025 ESMO Women for Oncology Award, Dr Natasha Leighl stresses the importance of passing along learnings, support and opportunities to others
International collaboration and a shared vision are key to improving cancer patients’ lives
The 2025 ESMO Lifetime Achievement Awardee, Prof. Rolf Stahel, reflects on the role of the oncology community to drive progress in cancer care
Personalising cancer treatment with AI and digital pathology
Leveraging artificial intelligence and digital pathology, oncology is entering a transformative stage where advanced image analysis and AI-driven biomarkers enable personalised cancer treatment decisions.
Status and trends in digital pathology
Pathology is going digital. More than 50 AIs cleared for diagnostic use are now available. This article summarises the status quo and gives an outlook of upcoming emerging technologies.